Adcytherix is a clinical‑stage biopharma that creates next‑generation antibody‑drug conjugates (ADCs) by linking clinically validated antibodies to innovative payloads derived from already approved cancer drugs. Their platform uses advanced conjugation chemistry to improve stability, control payload release, and overcome resistance mechanisms, expanding the therapeutic window for high‑unmet‑need solid tumors. The company’s pipeline targets cancers that are refractory to existing ADCs, offering more precise and tolerable oncology therapies.

Aptadir Therapeutics is developing RNA inhibitor-based therapeutics that selectively inhibit DNA methyltransferase 1 (DNMT1) to reprogram aberrant DNA methylation associated with intractable cancers and genetic conditions. Their platform utilizes modified RNA oligonucleotides for global inhibition and gene-specific sequences for locus-specific modulation, offering a targeted approach with reduced toxicity compared to existing therapies.

Argo is a social streaming platform that enables creators and fans to monetize video content through a coin-based reward system, facilitating direct financial support for creators. The platform addresses the inefficiencies in traditional monetization methods by allowing users to discover and share content while earning rewards for their engagement.

Avation Medical has developed the Vivally® System, a wearable physiologic closed-loop neuromodulation device that utilizes transcutaneous tibial nerve stimulation to treat overactive bladder (OAB) symptoms at home. This FDA-cleared system allows patients to manage urinary urgency and urge urinary incontinence with just 30 minutes of use, one to three times a week, while tracking their progress through a mobile application.

Biovitae utilizes UV-free natural white LED technology to continuously sanitize air and surfaces, effectively eliminating viruses, bacteria, and fungi in various environments. This solution addresses the problem of indoor air pollution and microbial contamination, significantly reducing the risk of infections and allergies for people and animals.

Cadence Neuroscience is developing a neuromodulation system that detects specific brain signals and delivers targeted electrical stimulation to modify neural circuit activity. This technology aims to provide personalized treatment options for epilepsy and other neurological disorders that are inadequately managed by existing therapies.

CoMind develops a non‑invasive neuromonitoring system that uses a lightweight adhesive forehead sensor, wavelength‑modulated laser, and interferometric time‑of‑flight detection to continuously measure cerebral blood flow, intracranial pressure, autoregulation, and brain tissue oxygenation at the bedside. The high‑speed optical data are processed in real time and can be displayed on dedicated monitors or integrated with existing ICU and operating‑room equipment, giving clinicians continuous, actionable neurophysiological insights without invasive catheters.

Uses the Revenir™ Product Engine to model and analyze the full spectrum of protein conformations derived from a single amino acid sequence, leveraging biophysics, machine learning, and computational chemistry. This approach enables the discovery of therapeutics that correct misfolded proteins and address diseases like genetic obesity and Parkinson’s, significantly improving the speed and accuracy of drug development compared to traditional methods.

Damona Pharmaceuticals is developing therapies that restore synaptic connections between brain cells to reverse cognitive deficits, which impair understanding, memory, and clear thinking. By targeting the underlying mechanisms of cognitive impairment, the company aims to enhance cognitive function for patients affected by these conditions.

Elkedonia is developing a novel neuroplastogen for depression treatment, utilizing a precision medicine approach to induce neuroplasticity. This therapeutic candidate targets intracellular neuronal events with a unique mechanism of action, aiming to provide fast-acting relief without common antidepressant side effects.

Extend offers a document processing platform that utilizes an in-house AI workforce to transform unstructured documents into actionable data, enabling faster decision-making and operational efficiency. The platform supports various file formats and automates complex workflows, allowing businesses to reduce manual processing time and improve accuracy in critical tasks.

Freya Biosciences develops microbial immunotherapies that target immune dysregulation and inflammation associated with reproductive health conditions such as infertility, endometriosis, and preterm birth. By engineering live microbes to restore a healthy vaginal microbiome, the company aims to improve clinical outcomes for women undergoing IVF and those facing reproductive system disorders.

GenEp is a pre-clinical biotechnology company focused on developing novel therapeutic solutions based on proprietary genetic sequencing technologies. The company aims to address unmet medical needs by leveraging its intellectual property to advance drug discovery and development processes.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Laigo Bio develops SureTACs, bispecific antibodies that facilitate the targeted degradation of membrane proteins linked to tumors and neurological diseases by promoting their ubiquitination and subsequent lysosomal removal. This technology addresses the challenge of treating previously undruggable targets, enhancing therapeutic specificity and efficacy in oncology and beyond.

MapLight Therapeutics utilizes optogenetics, STARmap, and transcriptomics to identify and target specific neural circuits involved in brain disorders. The company aims to develop therapeutics that provide effective treatment options for conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder, addressing the limitations of current therapies.

The startup develops anti-miRNA therapies aimed at treating neurological disorders, specifically targeting the underlying mechanisms of epilepsy. By providing transformative disease modification, the company enables healthcare professionals to offer more effective treatment options for patients suffering from this condition.

Noctrix Health develops a clinically validated wearable therapy utilizing Tonic Motor Activation (TOMAC) technology to manage symptoms of Restless Legs Syndrome (RLS). This drug-free solution addresses the significant discomfort and sleep disturbances experienced by millions of Americans affected by RLS, offering a viable alternative to traditional pharmaceutical treatments.

Nuclidium provides a cyclotron‑produced copper‑61/‑67 radiopharmaceutical platform that combines PET imaging and targeted beta‑therapy within a single chelator‑ligand framework. The matched isotopic pair enables accurate dosimetry, streamlined manufacturing, and lower per‑dose costs, expanding access for nuclear medicine and oncology departments.

Nuevocor develops NVC-001, a mechanobiology‑focused genetic medicine that uses gene‑editing to correct LMNA mutations in cardiomyocytes, restoring nuclear envelope function and stabilizing heart structure. The therapy aims to provide a disease‑modifying alternative to cardiac transplant for patients with LMNA‑related dilated cardiomyopathy, targeting specialty cardiac centers worldwide.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

Pretzel Therapeutics develops therapies targeting mitochondrial dysfunction by utilizing advanced mitochondrial biology techniques. This approach addresses over 50 diseases linked to genetic mitochondrial disorders, affecting 1 in 5,000 individuals.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Reya operates as a high-speed decentralized exchange (DEX) built as a based-rollup on Ethereum, offering traders millisecond execution for perpetuals, spot, staking, and RWA markets. It provides TradFi-level performance with gasless trades, unified margin, and self-custody, ensuring Ethereum-grade security and verifiable onchain settlement. The platform aims to deliver a zero-compromise venue where traders access global markets with speed, low latency, and full control over their assets.